首页|期刊导航|Oncology Research|Lorlatinib and Amivantamab:A Paradigm Shift in EGFR and ALK Positive NSCLC,with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making

Lorlatinib and Amivantamab:A Paradigm Shift in EGFR and ALK Positive NSCLC,with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making

Paolo Maione Valentina Palma Cesare Gridelli

Oncology Research2026，Vol.34Issue(4)：P.871-880,10.

Oncology Research2026，Vol.34Issue(4)：P.871-880,10.DOI:10.32604/or.2026.072992

Lorlatinib and Amivantamab:A Paradigm Shift in EGFR and ALK Positive NSCLC,with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making

Paolo Maione ¹Valentina Palma ²Cesare Gridelli¹

作者信息

1. Division of Medical Oncology,S.G.Moscati Hospital,Avellino,83100,Italy
2. Division of Medical Oncology,S.G.Moscati Hospital,Avellino,83100,Italy Division of Medical Oncology,Universitàdegli Studi della Campania“Luigi Vanvitelli”,Napoli,80121,Italy
折叠

摘要

关键词

Non-small cell lung cancer/shared-decision making/amivantamab/lorlatinib/osimertinib/alectinib/brigatinib

分类

医药卫生

引用本文复制引用

Paolo Maione,Valentina Palma,Cesare Gridelli..Lorlatinib and Amivantamab:A Paradigm Shift in EGFR and ALK Positive NSCLC,with More Effective but More Toxic Treatments Requiring a Well-Structured Shared Decision Making[J].Oncology Research,2026,34(4):P.871-880,10.

Oncology Research

ISSN：0965-0407

访问量0

下载量0

段落导航